Compare Ginkgo Bioworks Holdings Inc (DNA) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs McCormick & Company, Incorporated — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while McCormick & Company, Incorporated trades at $52.85 (market cap $14.21B). The key difference: McCormick & Company, Incorporated is far larger — about 24.1× Ginkgo Bioworks Holdings Inc's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MKC | |
|---|---|---|
Market Cap | $590.53M | $14.21B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $72.81 |
52-Week Low | $5.48 | $45.60 |
Enterprise Value | $627.78M | $18.81B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
McCormick (MKC) trades at $53.75, up 2.48% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, while valuation metrics like a P/E of 8.94 appear attractive. Recent Q2 2026 earnings beat estimates, and the company reaffirmed its 2026 outlook, supported by the transformative Unilever Foods deal announced in July 2026.
Outlook is positive with a consensus price target of $59.67 offering 11% upside, driven by margin recovery and strategic acquisitions. Risks include soft consumer volumes in the Americas and integration challenges from the Unilever deal. The stock presents a value opportunity with a 4% dividend yield, but investors should monitor volume trends and deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
